S-1: Cingulate Inc. Files for Resale of 1.5 Million Shares by Lincoln Park Capital

Cingulate Inc. has filed a registration statement for the resale of up to 1,500,000 shares of its common stock by Lincoln Park Capital Fund, LLC.

Summary

• Cingulate Inc. has filed a Form S-1 registration statement with the SEC to register the resale of up to 1,500,000 shares of its common stock by Lincoln Park Capital Fund, LLC.
• These shares may be issued and sold to Lincoln Park under a purchase agreement dated April 24, 2023.
• Cingulate will not receive any proceeds from the resale of shares by Lincoln Park, but may receive up to $4,713,220.68 from the sale of Purchase Shares to Lincoln Park.
• As of September 24, 2024, Cingulate had 3,044,165 shares of common stock issued and outstanding.
• The last reported sale price of Cingulate's common stock on Nasdaq on September 24, 2024 was $5.01 per share.
• The company is an emerging growth company and is subject to reduced public company reporting requirements.
• Cingulate effected a 1-for-12 reverse stock split on August 9, 2024.
• Investing in Cingulate's securities is highly speculative and involves a high degree of risk.

Sentiment

Score: 4

Explanation: The document is largely factual and related to a stock offering. While it highlights potential benefits, it also acknowledges risks and dilution, resulting in a neutral to slightly negative sentiment.

Positives

• The company has the potential to receive up to $4,713,220.68 in gross proceeds from the sale of shares to Lincoln Park, which can be used for research and development and commercialization activities.
• The company has shareholder approval to issue shares to Lincoln Park exceeding 19.99% of outstanding shares prior to the Purchase Agreement.

Negatives

• The sale of shares to Lincoln Park may cause dilution to existing stockholders.
• The market price of the common stock could decrease due to the sale of shares by Lincoln Park.
• The company's management has broad discretion over the use of the net proceeds.
• Investing in the company's securities is highly speculative and involves a high degree of risk.

Risks

• The company may not be able to sell all 1,500,000 Purchase Shares in this offering.
• Investors who buy shares at different times will likely pay different prices.
• The sale or issuance of common stock to Lincoln Park may cause dilution.
• The company's management will have broad discretion over the use of the net proceeds.
• The company's lack of operating history and need for additional capital.

Future Outlook

The company may sell shares of common stock to Lincoln Park from time to time over a 36-month period. The timing and amount of sales are at the company's sole discretion and depend on market conditions and other factors.

Industry Context

The company is targeting the ADHD treatment market, which has an estimated US market size of over $23 billion as of November 2023.

Stakeholder Impact

• Existing stockholders may experience dilution of their ownership.
• The market price of the common stock could be affected by the sales of shares by Lincoln Park.
• The company may use the proceeds from the sales to fund research and development and commercialization activities.

Next Steps

• The SEC must declare the registration statement effective.
• The company may, at its discretion, direct Lincoln Park to purchase shares of common stock.
• Lincoln Park may resell the shares of common stock.

Key Dates

Keywords

Cingulate, Lincoln Park, common stock, resale, registration statement, ADHD, financing, securities, shares